Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Patients (DARWIN1)



Status:Completed
Conditions:Arthritis, Rheumatoid Arthritis
Therapuetic Areas:Rheumatology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:July 2013
End Date:June 2015

Use our guide to learn which trials are right for you!

Randomized, Double-blind, Placebo-controlled, Multicenter, Phase IIb Dose Finding Study of GLPG0634 Administered for 24 Weeks in Combination With Methotrexate to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Alone

- 595 patients suffering from active rheumatoid arthritis despite continued treatment
with methotrexate will be evaluated for improvement of disease activity (efficacy) when
taking GLPG0634 (3 different doses - 50mg, 100mg and 200mg daily -, each evaluated as
QD and BID regimen) or matching placebo for 24 weeks.

- During the course of the study, patients will also be examined for any side effects
that may occur (safety and tolerability), and the amount of GLPG0634 present in the
blood (Pharmacokinetics) as well as the effects of GLPG0634 on disease- and mechanism
of action-related parameters in the blood (Pharmacodynamics) will be determined. Also,
the effects of different doses and dose regiments of GLPG0634 administration on
subjects' disability, fatigue, and quality of life will be evaluated.

- Treatment duration will be 24 weeks in total.

- However, at Week 12, subjects on placebo who have not achieved a 20% improvement in
swollen joint count(SJC66) and tender joint count (TJC68) will be re-randomized
(automatically via interactive voice/web response [IXRS]) to treatment to receive
GLPG0634 100 mg q.d. or 50 mg b.i.d. doses in a blinded fashion, subjects on 50 mg q.d.
who have not achieved a 20% improvement in SJC66 and TJC68 will be assigned to 100 mg
q.d. and subjects on 25 mg b.i.d. who have not achieved a 20% improvement in SJC66 and
TJC68 will be assigned to 50 mg b.i.d. All will continue the study until Week 24.

- Subjects in the other groups will maintain their randomized treatment until Week 24.

Inclusion Criteria:

- male or female subjects who are ≥18 years of age, on the day of signing informed
consent,

- have a diagnosis of RA since at least 6 months and meeting the 2010 ACR/EULAR
criteria of RA and ACR functional class I-III,

- have ≥6 swollen joints (from a 66 joint count) and

≥8 tender joints (from a 68 joint count) at Screening and at Baseline,

- Screening serum c-reactive protein ≥0.7 x upper limit of laboratory normal range
(ULN),

- have received MTX for ≥6 months and have been on a stable dose (15 to 25 mg/week) of
MTX for at least 4 weeks prior to Screening and willing to continue on their current
regimen for the duration of the study. Stable doses of MTX as low as 10 mg/week are
allowed when there is documented evidence of intolerance or safety issues at higher
doses.

Exclusion Criteria:

- current therapy with any disease-modifying anti-rheumatic drugs (DMARD) other than
MTX,

- current or previous RA treatment with a biologic DMARD, with the exception of
biologic DMARDs administered in a single clinical study setting more than 6 months
prior to Screening (12 months for rituximab or other B cell depleting agents), where
the biologic DMARD was effective, and if discontinued, this should not be due to lack
of efficacy,

- previous treatment at any time with a cytotoxic agent, other than MTX, before
Screening.
We found this trial at
29
sites
Austin, Texas 78705
?
mi
from
Austin, TX
Click here to add this to my saved trials
Boca Raton, Florida
?
mi
from
Boca Raton, FL
Click here to add this to my saved trials
?
mi
from
Buenos Aires,
Click here to add this to my saved trials
Clarksburg, West Virginia 26301
?
mi
from
Clarksburg, WV
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Duncansville, Pennsylvania 16635
?
mi
from
Duncansville, PA
Click here to add this to my saved trials
Frederick, Maryland 21702
?
mi
from
Frederick, MD
Click here to add this to my saved trials
Gainesville, Georgia
?
mi
from
Gainesville, GA
Click here to add this to my saved trials
?
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Greenville, North Carolina 27834
?
mi
from
Greenville, NC
Click here to add this to my saved trials
Hagerstown, Maryland 21740
?
mi
from
Hagerstown, MD
Click here to add this to my saved trials
?
mi
from
Hemet, CA
Click here to add this to my saved trials
Houston, Texas 77098
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Huntsville, AL
Click here to add this to my saved trials
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
Lansing, Michigan 48910
?
mi
from
Lansing, MI
Click here to add this to my saved trials
Meridian, Idaho
?
mi
from
Meridian, ID
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73103
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Ormond Beach, Florida 32174
?
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
Palm Desert, California 92260
?
mi
from
Palm Desert, CA
Click here to add this to my saved trials
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Rochester, Minnesota 55905
?
mi
from
Rochester, MN
Click here to add this to my saved trials
Seattle, Washington 98104
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Springfield, Illinois 62704
?
mi
from
Springfield, IL
Click here to add this to my saved trials
?
mi
from
Venice, FL
Click here to add this to my saved trials
?
mi
from
Victoria, TX
Click here to add this to my saved trials
Victorville, California
?
mi
from
Victorville, CA
Click here to add this to my saved trials
West Hills, California 91307
?
mi
from
West Hills, CA
Click here to add this to my saved trials
?
mi
from
Wichita, KS
Click here to add this to my saved trials